SS Innovations approved for Nasdaq listing; trading begins April 25 under SSII

SS Innovations International, Inc.

Common stock approved for listing on Nasdaq Capital Market; trading begins April 25, 2025 under symbol SSII.
Installed 80 SSi Mantra systems in 75 hospitals; performed 3,500+ surgeries including 195 robotic cardiac surgeries with zero device-related mortality.
Received CDSCO approval for telesurgery/tele-proctoring; performed 16 telesurgeries including world's first robotic cardiac telesurgery up to 1,200 miles.
FY2024 revenue $20.6M (+251% YoY); gross margin 40.9% (up from 12.3% in 2023).
Pursuing EU CE Mark (late 2025) and U.S. FDA approval (early 2026) for SSi Mantra system.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.